Goods & Services

Education, entertainment and sport services; Educational services provided by universities; Providing classroom instruction at the university level; Training; Further education. Scientific services; Scientific research; Advisory services relating to science; Scientific services and research relating thereto.

Abstract

Uncontrolled secretion of extracellular matrix (ECM) proteins such as collagen can lead to excessive scarring and fibrosis and compromise tissue function. Despite the widespread occurrence of fibrotic diseases and scarring, effective therapies are lacking. The invention provides inhibitors of TANGO1 activity and methods of use thereof. In particular, the invention relates to peptide inhibitors capable of preventing TANGO1 heterodimerisation and/or homodimerisation and thereby prevent collagen export from the endoplasmic reticulum. The inhibitors of the invention are particularly useful for use in methods of treating fibrotic diseases, such as scleroderma.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention relates to monoclonal human antibodies or antigen-binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the monoclonal antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1. The present invention further relates to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention relates to monoclonal human antibodies or binding fragments thereof which are directed against the V3 glycan site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C12N 15/13 - Immunoglobulins

Abstract

The present invention provides an isolated protein exhibiting an antiaggregating activity and/or disaggregating activity toward a target protein comprising an extended polyQ stretch. The protein comprises a Zn2+75-8075-80E and x is any amino acid. The nucleic acid construct encoding said protein as well as the corresponding mRNA sequence are also provided. The protein, the nucleic acid construct or mRNA sequence are for use in a method for prevention or treatment of a neurodegenerative disease that is caused by aggregates comprising at least one target protein and/or by the mRNA encoding for said target protein, wherein the target protein causes e.g. Huntington's disease or Machado-Joseph disease.

IPC Classes  ?

• C12N 9/50 - Proteinases
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an Inhibitor of κB (IκB) Kinase (IKK)/Nuclear Factor κB (NFκB)-signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention. The invention further pertains to a method of treatment and/or prevention of a proliferative disease in a subject, the method comprising administering to the subject as single treatments or one or more combinatorial treatments, either sequentially or concomitantly, a therapeutically effective amount of inhibitors of RIPK1, inhibitors of IKK/NFκB-signalling, and inhibitors of BCL-2.

IPC Classes  ?

• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a dual-fluorescence dye compound, comprising a fluorescent dye A and a fluorescent dye B, wherein: - fluorescent dye A and fluorescent dye B are covalently bonded to one another; - the emission maxima of fluorescent dye A and fluorescent dye B are separated by at least 100 nm, measured at 23°C, pH 5.8; - fluorescent dye A is pH sensitive and at pH 7.4 has at most 20% of the fluorescence intensity it has at pH 5; - the dual-fluorescence dye compound is lipophilic.

IPC Classes  ?

• C09B 11/24 - Phthaleins containing amino groups
• C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines
• C09B 69/00 - Dyes not provided for by a single group of this subclass
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a peptide comprising the amino acid sequence LVESCKEAFWDRCLSVINLMSSKM according to SEQ ID No. 1 wherein the peptide is linked to a trans-activator of transcription (TAT) domain, or a pharmaceutically acceptable salt thereof, and its use in the treatment of axonal damage in diabetes.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/16 - HIV-1
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The invention provides methods and means for the inhibition or neutralisation of death receptor/death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and/or the Toll-like receptor family, and/or NOD-like receptor and/or of the signalling induced via these receptors, preferably in combination with each other and/or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/275 - NitrilesIsonitriles
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The present invention relates to novel a novel fusion protein combining a portion of the TRAIL-R2 receptor with an Fc polypeptide region, and use of the same in methods of treatment of disease, for example in the treatment of cancer.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof against Human Cytomegalovirus (HCMV), pharmaceutical compositions comprising such antibodies or antigenbinding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, as well as the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions, and the kits for use as a medicament, and in the treatment or prevention of an infection with Human Cytomegalovirus. The present invention further relates to nucleic acids encoding the aforementioned such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present disclosure relates to antibodies or antigen-binding fragments thereof against Pseudomonas aeruginosa, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by Pseudomonas aeruginosa. The present disclosure further relates to methods of treating, preventing or reducing the severity of an infection with Pseudomonas aeruginosa, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents

Abstract

A method for detecting a spectrum of an ion species comprises the steps of a) capturing a subset of ions comprising the ion species in an ion trap; b) thermalizing the ions captured in the ion trap by a buffer gas; c) exciting the thermalized ions in the ion trap by electromagnetic radiation such that a kinetic energy of the ion species in the ion trap changes; and d) detecting the ions leaving the ion trap and/or detecting the ions remaining in the ion trap via a detector. In addition, the disclosure relates to a method for demixing a mixture of two or more ion species with equal mass-to-charge ratio and a method for determining a mixing ratio of a mixture of two or more ion species with equal mass-to-charge ratio. The disclosure further relates to a device for carrying out the above methods.

IPC Classes  ?

• H01J 49/42 - Stability-of-path spectrometers, e.g. monopole, quadrupole, multipole, farvitrons

Abstract

The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/18 - Antivirals for RNA viruses for HIV

Goods & Services

Science and technology services; Medical research, Biological research, Genetic research, Clinical research and Pharmaceutical research services; Conducting of scientific studies; Natural science services; Medical, bacteriological and chemical research laboratory services; Creation and maintenance of computer databases; Creation and programming of computer software for databases; Inquiries, research in databases and on the Internet, for scientific and research purposes; Operating search engines; Creation of computer programs for medical, biological, genetic, clinical and pharmaceutical applications; Updating of computer software; Providing or rental of electronic memory space on the Internet (webspace). Human healthcare services; Medical and veterinary medical services; Pharmaceutical services; Medical clinic services; Ambulant medical care; Telemedicine services; Medical diagnostics, Diagnosis in biology, diagnosis in genetics, clinical diagnostics and pharmaceutical diagnostics; Medical consultancy and support provided by doctors and other specialised medical personnel; Medical treatment services; Medical health assessment services; Medical equipment rental; Rental of equipment for medical purposes; Development of individual physical rehabilitation programmes; Counselling services in the following fields: biology, genetic science and Pharmacy; Medical, biological, genetic, clinical and pharmaceutical laboratory services.

Goods & Services

Science and technology services; Medical research, Biological research, Genetic research, Clinical research and Pharmaceutical research services; Conducting of scientific studies; Natural science services; Medical, bacteriological and chemical research laboratory services; Creation and maintenance of computer databases; Creation and programming of computer software for databases; Inquiries, research in databases and on the Internet, for scientific and research purposes; Operating search engines; Creation of computer programs for medical, biological, genetic, clinical and pharmaceutical applications; Updating of computer software; Providing or rental of electronic memory space on the Internet (webspace). Human healthcare services; Medical and veterinary medical services; Pharmaceutical services; Medical clinic services; Ambulant medical care; Telemedicine services; Medical diagnostics, Diagnosis in biology, diagnosis in genetics, clinical diagnostics and pharmaceutical diagnostics; Medical consultancy and support provided by doctors and other specialised medical personnel; Medical treatment services; Medical health assessment services; Medical equipment rental; Rental of equipment for medical purposes; Development of individual physical rehabilitation programmes; Counselling services in the following fields: biology, genetic science and Pharmacy; Medical, biological, genetic, clinical and pharmaceutical laboratory services.

Abstract

The present invention pertains to a method for identifying a subject suffering from cancer as a responder or non-responder to fibroblast growth factor receptor 1 (FGFR1) inhibitor therapy. The method involves the determination of the presence or absence of a genetic alteration of the FGFR1 gene, wherein the genetic variation is a copy number variation caused by a Breakage-Fusion-Bridge-like (BFB-like) mechanism wherein the break is located within, or within close proximity of, the ORF of the FGFR1 gene. These breaks associate with FGFR inhibitor sensitivity, and intra-chromosomal tail-to-tail breaks in FGFR1 may work as a predictive therapeutic marker for an FGFR inhibitor therapy in cancer that can be used to stratify patients for FGFR-inhibitor therapy. Furthermore, provided are inhibitors of FGFR1 for use in the treatment of cancer, and a method for identifying a genetic biomarker associated with a disorder, such as cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention provides an isolated protein exhibiting an antiaggregating activity and/or disaggregating activity toward a target protein comprising an extended polyQ stretch. The protein comprises a Zn2+-binding region, wherein the conserved motif is HxxEHx75-80E and x is any amino acid. The nucleic acid construct encoding said protein as well as the corresponding mRNA sequence are also provided. The protein, the nucleic acid construct or mRNA sequence are for use in a method for prevention or treatment of a neurodegenerative disease that is caused by aggregates comprising at least one target protein and/or by the mRNA encoding for said target protein, wherein the target protein causes e.g. Huntington's disease or Machado-Joseph disease.

IPC Classes  ?

• C12N 9/50 - Proteinases
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present invention relates to a medicament for use in a method of preventing or treating cancer in a patient, wherein the medicament comprises at least two of the following populations of cells (i) to (iv): (i) a population of lymphokine-activated killer cells (LAKs), (ii) a population of cytokine-induced killer cells (CIKs), (iii) a population of γδ-T-cells, (iv) a population of tumor-specific T-cells (CTLs), wherein the population of cells in (i) to (iv) are derived from autologous cells from said patient or from allogeneic cells from a donor, and pharmaceutical composition, kit or kit-of-parts related thereto.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/20 - Interleukins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A closed intubation system includes at least one endotrache-al tube suitable for insertion into the trachea of a patient, a tubular connection to a ventilation device and an adapter arrangement with at least three cylindrically shaped receptacles for producing a gas-tight coupling between the endotracheal tube, the connection of the ventilation device and at least one further receptacle. The adapter arrangement includes an adaptor base body, an adaptor attachment, an eleastic tubular sheath, and an attachment connection.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61M 25/00 - CathetersHollow probes
• A61M 39/10 - Tube connectors or tube couplings

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention generally relates to antimicrobial polypeptides, and more specifically to antimicrobial polypeptides derived from C-type lectin domain family 3-member A (CLEC3A) having improved properties. The present invention further relates to pharmaceutical compositions comprising said polypeptides. The antimicrobial polypeptides are particularly useful in the treatment of bacterial infections, especially those caused by drug resistant bacteria.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof

Abstract

The invention describes a novel combination therapy strategy and screening approaches, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an inhibitor (IκB) kinase epsilon (IKKε), and a TANK binding kinase 1 (TBK1) inhibitor for the treatment and/or prevention of diseases associated with a modulated immune response, such as disorders associated with a type I interferon response. The invention provides such inhibitory compounds and their specific combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention. The invention further pertains to a method of treatment and/or prevention of a proliferative disease in a subject, the method comprising administering to the subject as single treatments or one or more combinatorial treatments, either sequentially or concomitantly, a therapeutically effective amount of inhibitors of RIPK1, inhibitors of IKKε – signaling, and inhibitors of TBK1. Further provided are approaches for screening and testing candidate kinase inhibitors for their applicability in a triple combination in accordance with the invention.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 37/04 - Immunostimulants

Abstract

The invention is related to a chimeric checkpoint receptor (CCR) fusion protein, a nucleic acid molecule encoding said fusion protein, a vector comprising said nucleic acid molecule, a host cell comprising said nucleic acid molecule and/or expressing the fusion protein, a method for providing said host cell, a pharmaceutical composition comprising said fusion protein, nucleic acid molecule or host cell, and said products for use as a medicament and in the treatment of B cell lymphoma.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors

Abstract

An interference filter for the wavelength-selective filtering of light includes a stack arrangement of layer structures which has two partially permeable mirror layer structures and an intermediate layer structure arranged between the two partially permeable mirror layer structures, wherein the two partially permeable mirror layer structures form an optical resonator with a characteristic resonator wavelength kβ. The material of the intermediate layer structure has, at an absorption wavelength, such an excitonic material resonance that the wavelength-dependent transmittance of the stack arrangement is determined in a wavelength range surrounding the absorption wavelength range by a strong coupling of the photons, located in the resonator, of the light with excitons of said material resonance.

IPC Classes  ?

• G02B 5/28 - Interference filters

Abstract

The present invention relates to near-infrared fluorescent heptamethine dyes of formula (I) and conjugates of such heptamethine dyes with favourable biodistribution and bleaching properties. The invention is further directed to the use of these compounds in diagnosis or in intraoperative surgery, in particular for use as contrast agents.

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present disclosure provides methods for mass-tag labeling of the cellular secretome and soluble components thereof, as well as mass-tagged soluble components of the cellular secretome. In certain embodiments, the disclosure provides methods for mass-tagging of extracellular vesicles (EVs) and mass-tagged EVs. Also provided are methods of using mass-tagged soluble components of the cellular secretome, such as mass-tagged EVs, mass-tagged viruses, or mass-tagged soluble proteins and peptides. These can be combined with other labeling strategies, such as cell barcoding to facilitate multiplexed and/or multi-dimensional analyses of the distribution, uptake, and effects of components of secretome (such as EVs).

IPC Classes  ?

• G01N 33/531 - Production of immunochemical test materials
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to a system (10) for providing an optical signal, comprising an energy transducer (12) and a light source (14), wherein the energy transducer (12) comprises at least two materials (16a, 18a) and, as a magnetoelectric transducer, is configured to generate electrical energy on the basis of an alternating magnetic field, wherein the light source (14) is arranged on the energy transducer (12) and electrically conductively contacts a first surface (15) of the energy transducer (12), said first surface functioning as an electrode (16), and wherein it is not via a cable connection that the light source (14) is in electrical contact with the energy transducer (12). The invention furthermore relates to the use of the above system (10) for optically stimulating a nerve cell. In addition, the invention relates to a method for producing a system (10) for providing an optical signal.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

The invention relates to a method for detecting a spectrum (60) of a molecular species, comprising the steps of - generating an analogue polychromatic excitation signal (20) in a high frequency range (46), - coupling the excitation signal (20) into an excitation and detection apparatus (22) to generate a background measurement signal (24) and/or to excite the molecular species introduced into the excitation and detection apparatus (22), - detecting the background measurement signal (24) and/or an analogue measurement signal using the excitation and detection apparatus (22), - generating an analogue cancellation signal (56) taking the detected background measurement signal (24) into account or generating the analogue cancellation signal (56) taking the detected measurement signal into account, the cancellation signal (56) being such that it is phase-shifted at least proportionally to a detectable analogue background signal (24, 28) by 180 degrees, - generating a sum signal taking the cancellation signal (56) and the measurement signal into account, - amplifying the sum signal, and - detecting the spectrum (60) of the molecular species by digitizing the amplified sum signal. The invention also relates to a spectrometer (10) for detecting a spectrum (60) of a molecular species.

IPC Classes  ?

• G01J 3/10 - Arrangements of light sources specially adapted for spectrometry or colorimetry
• G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry
• G01J 3/433 - Modulation spectrometryDerivative spectrometry
• G01N 21/3581 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation

Abstract

11) inhibitor, an Inhibitor of κB (IκB) Kinase (IKK)/Nuclear Factor κB (NFκB) – signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention. The invention further pertains to a method of treatment and/or prevention of a proliferative disease in a subject, the method comprising administering to the subject as single treatments or one or more combinatorial treatments, either sequentially or concomitantly, a therapeutically effective amount of inhibitors of RIPK1, inhibitors of IKK/NFκB – signalling, and inhibitors of BCL-2.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 15/13 - Immunoglobulins
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• C07K 14/475 - Growth factorsGrowth regulators
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography

Abstract

The present invention relates to a medicament for use in a method of preventing or treating cancer in a patient, wherein the medicament comprises at least two of the following populations of cells (i) to (iv): (i) a population of lymphokine-activated killer cells (LAKs), (ii) a population of cytokine-induced killer cells (CIKs), (iii) a population of γδ-T-cells, (iv) a population of tumor-specific T-cells (CTLs), wherein the population of cells in (i) to (iv) are derived from autologous cells from said patient or from allogeneic cells from a donor, and pharmaceutical composition, kit or kit-of- parts related thereto.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

gene. These breaks associate with FGFR inhibitor sensitivity, and intra-chromosomal tail-to-tail breaks in FGFR1 may work as a predictive therapeutic marker for an FGFR inhibitor therapy in cancer that can be used to stratify patients for FGFR-inhibitor therapy. Furthermore, provided are inhibitors of FGFR1 for use in the treatment of cancer, and a method for identifying a genetic biomarker associated with a disorder, such as cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a closed intubation system (1) comprising: at least one endotracheal tube (3) suitable for insertion into the trachea of a patient; a tubular connection to a respiratory device (2); and an adapter arrangement (4) having at least three cylindrical receptacles (6, 7, 8) for establishing a gas-tight coupling between the endotracheal tube, the connection of the respiratory device, and at least one further receptacle. The adapter arrangement comprises at least: a) an adapter main body (5) which is T-shaped owing to the arrangement of the receptacles and has at least one shut-off device (9), the shut-off device being designed to open or close the air path between the further receptacle (8) and the two receptacles (6, 7) for the respiratory device and the endotracheal tube in a gas-tight manner; b) an adapter attachment (10) which can be coupled to the further receptacle, the adapter attachment being connectable to the adapter main body in a gas-tight manner via a seal and being mechanically fixable thereto by means of holding means; c) an elastic, tubular sheath (11), one end of which is gas-tightly arranged on the adapter attachment; d) an attachment (12) connected in a gas-tight manner to the other end of the elastic, tubular sheath, the attachment comprising a passage to the tubular sheath and having a sealing device arranged therein, the sealing device being designed to receive cylindrical devices and to guide said devices in a displaceable and gas-tight manner through the attachment, the tubular sheath, the adapter attachment, the adapter main body, and the endotracheal tube.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

The present invention relates to a new biomarkers for the diagnosis of Alzheimer's disease (AD). More specifically, the present invention relates to the predictive detection of Alzheimer's disease (AD) in a mammal. The biomarkers, methods and kits provided enable prediction of progressions of Mild cognitive impairment (MCI) to AD by measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a method and a cartridge for carrying out a reaction between a sample fluid (9) and at least one reagent, in particular for performing LAMP assays, the cartridge comprising at least one pair of ducts (2, 3) that includes a sample duct (2) into which a sample fluid (9) can be introduced as well as a reagent duct (3) into which a reagent fluid can be introduced; the sample duct (2) and the reagent duct (3) intersect, in particular so as to allow sample fluid (9) to be transferred from the intersection zone (5) into the reagent duct (3).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to an electrode comprising an organic compound prepared by polymerization of a triaryl amine having at least one reactive polymerizable group, whereby the organic compound has at least a bimodal pore size distribution. Moreover, the present invention relates to a method for the preparation of such an electrode.

IPC Classes  ?

• H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
• H01M 4/04 - Processes of manufacture in general
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms

Abstract

The invention relates to a device for the transplantation of a Descemet's membrane-endothelium graft (5), comprising a longitudinal tube (1), the tube (1) having an inner cavity (2), an inlet opening (3) at its proximal end (PE) through which it is possible to introduce the graft (5) into the cavity (2), and an outlet opening (4) at its distal end (DE) through which it is possible to eject the graft (5) from the cavity (2), particularly into the anterior eye chamber of a patient, a guiding element (6) situated in the cavity (2) of the tube (1) extending from the proximal end area of the tube (1) or device towards the distal end area of the tube (1) or device and having an increasing cross section at least along a part of its extension, particularly by increasing the width of the guiding element (6) more than the height of the guiding element (6), wherein the guiding element (6) extending beyond the outlet opening (4) of the tube into the exterior environment of the tube (1), and having the distal end (6b) of the guiding element (6) being positioned outside of the tube (1) in front of the outlet opening (4) of the tube (1).

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61F 9/007 - Methods or devices for eye surgery

Abstract

The invention provides methods and means for the inhibition or neutralisation of death receptor/death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and/or the Toll-like receptor family, and/or NOD-like receptor 5 and/or of the signalling induced via these receptors, preferably in combination with each other and/or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/12 - Antivirals
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to novel a novel fusion protein combining a portion of the TRAIL-R2 receptor with an Fc polypeptide region, and use of the same in methods of treatment of disease, for example in the treatment of cancer.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The invention relates to an interference filter (10) for the wavelength-selective filtering of light, having a stack arrangement (18) of layer structures (16, 20, 22, 24, 32, 42, 44) which has two partially permeable mirror layer structures (20, 22) and an intermediate layer structure (24, 32) arranged between the two partially permeable mirror layer structures (20, 22), wherein the two partially permeable mirror layer structures (20, 22) form an optical resonator (26) with a characteristic resonator wavelength kß. The material of the intermediate layer structure (24) has, at an absorption wavelength 1A, such an excitonic material resonance that the wavelength-dependent transmittance T(A) of the stack arrangement is determined in a wavelength range surrounding the absorption wavelength range 1A by a strong coupling of the photons, located in the resonator (26), of the light with excitons of said material resonance. The invention also relates to the use of a corresponding stack arrangement (18) of layer structures (16, 20, 22, 24, 32, 42, 44) as an interference filter (10).

IPC Classes  ?

• G02B 5/28 - Interference filters

Abstract

The present invention relates to antibodies or binding fragments thereof against SARS-related coronavirus, a pharmaceutical composition comprising such antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention relates to chemical compounds which can be used in particular as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting Ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of these compounds as pharmaceutical agents and the use of the pharmaceutical agents for the treatment of tumor diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.

IPC Classes  ?

• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• A61P 9/12 - Antihypertensives
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration

Abstract

The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to a method for detecting malignant kidney cancer in an individual, said method conducted in vitro comprising the steps of providing a body fluid sample, in particular a urine sample, obtained from the individual, and determining one or more biomarker levels selected from the group consisting of the Mxi-2 level, the Vim3 level, the MAPKp38 level and the Atg7 level in the sample. Further, the present invention refers to a kit and a dipstick for use in such method.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Methods, kits, and active ingredients for diagnosing or treating arthritis or a degenerative disease of the skeletal system, or for selection of subjects for therapy. The methods for diagnosing arthritis involve the detection of an autoantibody, which is associated with arthritis, or excluding the presence of an autoantibody against collagen II. The methods for diagnosing a degenerative disease of the skeletal system, involve the detection of an autoantibody against thrombospondin-4 or COMP. The kits contain a detection agent for an autoantibody and can be used for diagnosing arthritis or a degenerative disease of the skeletal system. The active ingredient can be used for treating or preventing autoimmune-associated arthritis.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/16 - Animal cells

Abstract

The invention relates to a device for the preparation of a Descemet's membrane-endothelium graft comprising a bowl (1) with an inner bottom (2) and a sidewall (3) surrounding the bottom (2), particularly the bowl (1) being configured to receive a fluid and a Descemet's membrane-endothelium graft or a donor cornea graft comprising a Descemet's membrane-endothelium graft floating in the fluid, a preparation area (4) positioned in a first part (2a) of the inner bottom (2) of the bowl (1), particularly for receiving and preparing the graft prior to transportation, a transfer area (5) positioned in a second part (2b) of the inner bottom (2) between the preparation area (4) and an outlet opening (6) in the sidewall (3), particularly the opening (6) being entirely positioned below the upper rim of the sidewall (3).

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61F 2/16 - Intraocular lenses
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

68Ga]HBED-CC-PSMA representing currently the gold standard for the diagnosis of recurrent PCa. Furthermore, this probe is easily accessible on a preparative scale in commercially available automated synthesis modules like GE FASTlab and TRACERlab FX N Pro. Consequently, the novel probe is a valuable tool for the visualization of ganglia and reendothelialization as well as for the diagnosis of glioma, neuropathic pain and atherosclerotic plaques.

IPC Classes  ?

• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
• A61M 36/14 - Radioactive dressings
• C07D 213/82 - AmidesImides in position 3
• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine/threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

IPC Classes  ?

• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Abstract

The present invention relates to an electrode comprising an organic compound prepared by polymerization of a triaryl amine having at least one reactive polymerizable group, whereby the organic compound has at least a bimodal pore size distribution. Moreover, the present invention relates to a method for the preparation of such an electrode.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
• H01M 4/02 - Electrodes composed of, or comprising, active material

Goods & Services

Retailing, including via the internet, relating to bags adapted for laptops, mobile telephone cases, audiobooks, DVD's, CD ROM, floppy disks, USB flash drives, USB hubs, USB chargers, jewellery, ornaments, key rings and key chains and charms thereof, jewellery boxes and watch boxes, paper and cardboard, decoration and art materials and media, filtering materials of paper, bags, pouches and articles for packaging, wrapping and storage of paper, cardboard or plastics, stationary and teaching materials, adhesives for stationery or for household purposes, bibs of paper, printed matter; Retailing, including via the internet, in relation to umbrellas and parasols, canes, Luggage, handbags, pocket wallets and other object carriers, Tableware, cooking pot sets and containers, coffee mugs, Glassware, porcelain and earthenware, Household or kitchen utensils and containers (not of precious metal or coated therewith), Insulating containers, vessels and bottles, In particular for beverages and food, Cloths; Retailing, including via the internet, relating to textile goods and substitutes for fabrics, table covers, bed linen, bed blankets, towels, bath towels, headwear, clothing, footwear, accessories for clothing, sewing articles and decorative articles of textile, sporting articles and equipment, festive decorations, play articles, games, toys and novelties, electronic learning toys, sweets, muesli bars and energy bars. University services; Arranging and conducting of conferences, seminars, symposiums and meetings; Lending library services; Education, entertainment and sports; Distance-learning training courses; Nursery schools; Arranging and conducting of events for cultural, entertainment and sporting purposes; Film and video tape film production; Publishing and reporting; Publishing services (including electronic publishing services); Publishing of printed matter, in particular of teaching, instructional, course and/or viewing materials and/or research results, including in electronic form and on the internet (included in class 41); Rental of objects in connection with the providing of the aforesaid services, included in this class; Knowledge transfer by means of an information-technology based instructional, learning, knowledge, training and information environment (included in class 41), consultancy and information relating to the aforesaid services, Included in this class; Organising and conducting of instructional events. Universities, namely scientific research, scientific and technical appraisal, in particular in the subjects of biology, chemistry, pharmacy, educational sciences, psychology, historical and cultural sciences, mathematics, IT, medicine, philosophy, humanities, physics, politics, social sciences, legal sciences, veterinary medicine, economics, sports, languages, botany; Medical, veterinary and bacteriological laboratories; Creating pages on the Internet containing instructional, teaching, training and illustrative materials and research findings; Creating and updating computer programs; Providing an e-commerce platform on the Internet; Installing webpages on the Internet, for others; Science and technology services; Software as a service [SaaS]; Software design for others; Preparation of data processing programmes; Updating of computer software; Maintenance of computer software; Duplication of computer programs; Providing online, non-downloadable software; Computer system design; Platform as a service (PaaS); Electronic data storage; Off-site data backup; Converting; Providing electronic memory space on the Internet; Rental of computers and computer software; Computer rental; Rental of web servers; Computer technology consultancy; Information technology [IT] consultancy; Web site design consultancy; Rental of objects in connection with the providing of the aforesaid services, included in this class; Consultancy and information in relation to the aforesaid services, included in this class. Medical and veterinary medical services, Medical services, Wellness services relating to health and beauty care and spa services; Agriculture, horticulture and forestry services.

Abstract

The invention relates to a device for the transplantation of a Descemet's membrane-endothelium graft (5), comprising a longitudinal tube (1), the tube (1) having an inner cavity (2), an inlet opening (3) at its proximal end (PE) through which it is possible to introduce the graft (5) into the cavity (2), and an outlet opening (4) at its distal end (DE) through which it is possible to eject the graft (5) from the cavity (2), particularly into the anterior eye chamber of a patient, a guiding element (6) situated in the cavity (2) of the tube (1) extending from the proximal end area of the tube (1) or device towards the distal end area of the tube (1) or device and having an increasing cross section at least along a part of its extension, particularly by increasing the width of the guiding element (6) more than the height of the guiding element (6), wherein the guiding element (6) extending beyond the outlet opening (4) of the tube into the exterior environment of the tube (1), and having the distal end (6b) of the guiding element (6) being positioned outside of the tube (1) in front of the outlet opening (4) of the tube (1).

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61F 9/007 - Methods or devices for eye surgery

Abstract

The present invention relates to a non-aqueous ophthalmic composition comprising particles of a protein powder preparation suspended in a liquid vehicle comprising a semifluorinated alkane, wherein the particles of the protein powder preparation comprise an anti-VEGF protein selected from aflibercept or a sequence having at least 90% sequence identity to SEQ ID NO: 1. The composition is particularly suitable for the treatment of ocular neovascularization.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to methods for detecting a malignant tumor in an individual by means of determining the Vimentin variant 3 (Vim3) level in the individual's blood serum S and/or the accumulation of Vim3 polypeptide in cell nuclei. Furthermore, the present invention refers to an antineoplastic agent for use in a method for treating an individual bearing a malignant tumor, wherein said antineoplastic agent is a Vim3 inhibitor and/or wherein the malignant tumor is endothelin B receptor negative.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention relates to a method for determining the fertility of spermatozoa comprising detecting mitogen-activated protein kinase 14 iso form 3 (Mxi-2).The method may be a method for determining the fertility of spermatozoa contained in a sample S, said method comprising detecting the total content of the Mxi-2 in the sample S. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a method for determining the fertility of spermatozoa, said method comprising determining the total content of Vimentin variant 3 (Vim3) per spermatozoon and/or the spatial localization of the Vim3 in the spermatozoa, wherein a decreased amount of total content and/or decreased amount of (or even missing) accumulation of Vim3 in the mid piece of the spermatozoa indicates decreased fertility. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/563 - ImmunoassayBiospecific binding assayMaterials therefor involving antibody fragments

Abstract

6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]PSMA-1007 and [A118F]HBED-CC-PSMA. Unexpectedly, the 6-[18F]fluoro-2-alkoxy and 6-[18F]fluoro-4- alkoxy substituted analogs showed significant differences in accumulation in PSMA expressing prostate tumor cells. Whereas the 2-alkoxy derivative showed cellular uptake values higher than [18in vivoin vivo PET studies with 2- alkoxy-substituted probes demonstrated excellent visualization of PSMA positive ganglia with extremely high target to background ratio. In contrast, the 4-alkoxy substituted derivatives showed less favorable biodistribution with significantly lower uptake in PSMA positive tissues. Especially, the 18F-labeled 2-methoxy derivate ((2S)-2-({[(1 S)- 1 -carboxy-5- [(6-[18F] fluoro-2-methoxypyridin-3-yl)formamido]pentyl ]carbamoyl} -amino)pentanedioic acid) demonstrated exceptional clinical efficiency in detecting small PCa lesions, including those which could not be visualized with [68Ga]HBED-CC-PSMA representing currently the gold standard for the diagnosis of recurrent PCa. Furthermore, this probe is easily accessible on a preparative scale in commercially available automated synthesis modules like GE FASTlab and TRACERlab FX N Pro. Consequently, the novel probe is a valuable tool for the visualization of ganglia and reendothelialization as well as for the diagnosis of glioma, neuropathic pain and atherosclerotic plaques.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The invention relates to chemical compounds that can be used in particular as structural mimetics of proline-rich peptides. The compounds of the invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical active substances and to the use of the pharmaceutical active substances to treat tumor diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The invention relates to a neural sheath, in particular a spinal cord sheath, comprising a sheath tube (1), which at at least one circumferential position has a separating point (2) extending over the entire axial length of the sheath tube (1), at which separating point the sheath tube (1) can be opened and/or closed over the entire axial length, and in particular is closed in the intended use state. The invention further relates to the use of at least one sheath element (2), which can be formed, or is formed into a sheath tube (1), which at at least one circumferential position has a separating point (3) extending over the entire axial length of the sheath tube (1), at which the sheath tube (1) can be opened and/or closed over the entire axial length as a protective sheath for neural structures (6), in particular the spinal cord.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis

Abstract

The invention relates to a method for diagnosing arthritis, comprising the detection of an autoantibody, which is associated with arthritis, to a method for diagnosing a degenerative disease of the skeletal system, comprising the detection of an autoantibody against thrombospondin-4 or COMP, to a method for diagnosing arthritis, comprising excluding the presence of an autoantibody against collagen II, to a kit for diagnosing arthritis or a degenerative disease of the skeletal system, comprising a detection agent for an autoantibody, to the use of the kit for diagnosing arthritis or a degenerative disease of the skeletal system, to an active ingredient for use for treatment or preventing autoimmune-associated arthritis and to the diagnostic method for selection of subjects for therapy.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine/threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating cells or differentiated cells derived from the pluripotent stem cells, the method comprising the step of contacting the cell population with a compound according to the general formula (1).

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to methods for detecting a malignant tumor in an individual by means of determining the Vimentin variant 3 (Vim3) level in the individual's blood serum S and/or the accumulation of Vim3 polypeptide in cell nuclei. Furthermore, the present invention refers to an antineoplastic agent for use in a method for treating an individual bearing a malignant tumor, wherein said antineoplastic agent is a Vim3 inhibitor and/or wherein the malignant tumor is endothelin B receptor negative.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.g. defined herein is disclosed. Further, a method for the modification of a mutated AAV particle is disclosed allowing a specific modification of the same including an embodiment using a reagent addressing the cysteine residues for binding reaction such as a thioether binding.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to a method for detecting malignant kidney cancer in an individual, said method conducted in vitro comprising the steps of providing a body fluid sample, in particular a urine sample, obtained from the individual, and determining one or more biomarker levels selected from the group consisting of the Mxi-2 level, the Vim3 level, the MAPKp38 level and the Atg7 level in the sample. Further, the present invention refers to a kit and a dipstick for use in such method.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The invention relates to an inhibitor of Calcineurin B Homologous Protein 1 (CHP1) for use in a method for the treatment or prevention of a patient suffering from or being at risk of developing a disorder associated with a pathological calcium homeostasis, impaired vesicular trafficking and/or disturbed neuronal and/orneuromuscular synaptic function.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention relates to a method for determining the fertility of spermatozoa, said method comprising determining the total content of Vimentin variant 3 (Vim3) per spermatozoon and/or the spatial localization of the Vim3 in the spermatozoa, wherein a decreased amount of total content and/or decreased amount of (or even missing) accumulation of Vim3 in the mid piece of the spermatozoa indicates decreased fertility. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates generally to the field of molecular biology and concerns a conjugate comprising a beta 1,6-glucan binding polypeptide, or a beta 1,6-glucan binding fragment thereof, and a detectable label. Moreover, also encompassed by the invention are a fragment of the beta 1,6-glucan binding polypeptide that specifically binds to beta 1,6 glucans, a vector comprising a nucleic acid encoding for the beta 1,6-glucan binding polypeptide and a host cell or non-human organism comprising a nucleic acid encoding for the beta 1,6-glucan binding polypeptide and the use of said conjugate comprising a beta 1,6-glucan binding polypeptide, or a beta 1,6-glucan binding fragment thereof.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a device for the transplantation of a Descemet's membrane (2), comprising a longitudinal tube (1) having an inner cavity, an inlet opening (8) through which it is possible to introduce the Descemet's membrane (2) into the device, and an outlet opening (6) through which it is possible to eject the Descemet's membrane (2) from the device, especially into the anterior eye chamber of a patient, wherein the tube has, at least in the region of the outlet opening (6), a separation element (4) which protrudes from the inner wall region of the tube into the cavity, especially a first separation element (4), said separation element dividing the cavity at least regionally, in particular dividing it in a region close to the separation element (4).

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes

Abstract

The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• C07D 471/10 - Spiro-condensed systems
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A receiving container for a detector which operates in an ultrahigh vacuum or in a protective gas atmosphere that consists of high-purity gas. The receiving container has a receiving portion which forms at least a portion of the receiving space for the detector, and a cover for hermetically sealing the receiving space. A first sealing surface is arranged at the receiving portion and a second sealing surface matching the first sealing surface is arranged at the cover. Between the sealing surfaces a gasket is arranged. A securing device presses the cover against the receiving portion to provide a defined contact pressure of the gasket.

IPC Classes  ?

• H01L 31/0203 - Containers; Encapsulations
• G01T 1/24 - Measuring radiation intensity with semiconductor detectors
• H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions

Abstract

18F]DCFPyL. The key advantages of these inventive methods are efficiency, short time of preparation and excellent amenability to automation. A pharmaceutical composition containing at least one PSMA-specific PET tracers prepared by the inventive method is useful for positron emission tomography (PET) imaging, especially imaging prostate tumor.

IPC Classes  ?

• C07D 213/82 - AmidesImides in position 3
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
• C07K 1/13 - Labelling of peptides
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07D 237/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The invention relates to CPAP-tubulin inhibitors having the general formula (1) or a physiologically acceptable salt thereof; and their use as cancer therapeutics.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 35/00 - Antineoplastic agents

Abstract

A method of culturing Haematococcus species for manufacturing of astaxanthin comprising the steps of: - providing a substrate, - arranging the Haematococcus species on the surface of the substrate, - exposing the Haematococcus species arranged on the substrate to high light intensities from the beginning of a culturing process and avoiding a two-step culturing process of the Haematococcus species with a first step which is an initial culturing taking place by exposure of the Haematococcus species to low light energy followed by a second step of subsequent culturing of the Haematococcus species by exposure of the Haematococcus species to higher light energy than applied in the first step to induce astaxanthin formation, and optionally - harvesting the cultured Haematococcus species and/or - isolating astaxanthin.

IPC Classes  ?

• C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes

Abstract

Subject matter of the present invention is PSMA Binding molecules for use in diagnosis and/or imaging of pain. Diagnosis or imaging of pain may be the visualization of the location of the origin of pain and/or the determination of the etiology of pain and/or the determination of the pain intensity and/or the stratification of subjects suffering from pain.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

Abstract

The invention relates to fire extinguishing foams or concentrates thereof, these comprising a carbohydrate-containing siloxane surfactant.

IPC Classes  ?

• A62D 1/02 - Fire-extinguishing compositionsUse of chemical substances in extinguishing fires containing or yielding a gas phase, e.g. foams

Abstract

The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

Pharmaceutical composition comprising at least one compound having a structural formula selected of the isomers IA or IB: (IA) (IB) wherein R1 = H or alkyl or F or Cl or Br or I; R2, R3, R4 = are independently from each other H, methyl, ethyl or (R2 and R3) or (R3 and R4) are forming a methylene or ethylene bridging structure between the oxygen atoms linked to R2, R3 or R4; R5 = H or methyl; H, methyl or fluorinated or partially fluorinated methyl or ethyl; X = O or S; XR6 may also be F; Y = (CH2)m R7n (CH2)q with R7 = O, NH or NR8, R8 = alkyl, acyl or aryl and the proviso that (independently from each other) m, n, q = 0, 1, 2 and ∑(m+n+q) = 1, 2 or 3; Z = single or double bonded organic residue comprising methyl or methylene, =O, -OH, NHR, OR, NH2, NH-acyl, N3, triazole or substituted triazole, CH2-triazole, CH2-SH, CH2SR, CH2NH2, CH2NHR, CH2N3, CH2OR, CH2OC(O)OR (carbonate), CH2OC(O)NHR, CH2NHC(O)OR (carbamate), CH2NHC(O)NHR (urea), CH2NHC(S)NHR (thiourea) with R = alkyl, aryl, acyl, C(O)-, CH2-triazole.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Compounds and pharmaceutically acceptable salts of the compounds are useful in the treatment of neoplastic diseases or proliferative disorders. The compounds are formulated into pharmaceutical compositions, which can be used in methods of treating neoplastic diseases or proliferative disorders The compounds are useful to treat cancers such as prostate, pancreatic, lung, skin, breast, bladder, colon, and blood cancers. The compounds are represented by the following formula:

IPC Classes  ?

• C07C 203/04 - Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• C07C 309/76 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
• C07C 247/10 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
• C07C 69/78 - Benzoic acid esters
• C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
• A61K 31/621 - Salicylic acidDerivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
• C07C 69/86 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
• C07C 69/75 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of acids with a six-membered ring
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

The invention relates to a method for the in-situ production of fuel mixtures such as fuel-water mixtures, in particular (micro-/nano-) emulsions in internal combustion engines, and to an injection device for internal combustion engines that is suitable therefor.

IPC Classes  ?

• F02M 25/00 - Engine-pertinent apparatus for adding non-fuel substances or small quantities of secondary fuel to combustion-air, main fuel or fuel-air mixture
• F02M 25/022 - Adding fuel and water emulsion, water or steam
• F02M 25/03 - Adding water into the cylinders
• F02M 43/04 - Injectors peculiar thereto
• C10L 1/32 - Liquid carbonaceous fuels consisting of coal-oil suspensions or aqueous emulsions
• F02D 19/12 - Controlling engines characterised by their use of non-liquid fuels, pluralities of fuels, or non-fuel substances added to the combustible mixtures peculiar to engines working with non-fuel substances or with anti-knock agents, e.g. with anti-knock fuel
• F23K 5/12 - Preparing emulsions

Abstract

The invention relates to chemical compounds that can be used in particular as structural mimetics of proline-rich peptides. The compounds of the invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical active substances and to the use of the pharmaceutical active substances to treat tumor diseases. The chemical compounds of the invention can strongly inhibit the chemotaxis and motility of invasive tumor cells and thus can be used in the treatment and/or prevention of tumor metastases.

IPC Classes  ?

• C07K 5/12 - Cyclic peptides
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a receiving container (1) for a detector (100) which operates in an ultrahigh vacuum or in a protective gas atmosphere that consists of a high-purity gas. Said receiving container comprises a receiving part (3) which forms at least part of the receiving space (7) for the detector (100), and a cover (5) for hermetically sealing the receiving space (7). A first sealing surface (13) is arranged on the receiving part (3) and a second sealing surface (17) matching the first sealing surface (13) is arranged on the cover (5). Between the sealing surfaces (13, 17) a gasket (19) is arranged. A securing device (23) presses the cover (5) against the receiving part (3) to provide a defined contact pressure of the gasket (19).

IPC Classes  ?

• G01T 1/24 - Measuring radiation intensity with semiconductor detectors
• H01L 31/0203 - Containers; Encapsulations

Abstract

The invention relates to a fire fighting foam concentrate comprising a first surfactant, the first surfactant having an acid group as well as an oligosilane unit and/or oligosiloxane unit. The invention further relates to a method for extinguishing fires, comprising the steps of: providing a fire fighting foam concentrate; adding the fire fighting foam concentrate to water to obtain a mixture and bringing the fire into contact with the mixture; wherein the fire fighting foam concentrate is a fire fighting foam concentrate according to the invention. A further object of the invention is the use of a surfactant as an additive to fire fighting foams and/or fire fighting foam concentrates, the surfactant comprising an acid group as well as an oligosilane unit and/or oligosiloxane unit. An example is the following: (formula)

IPC Classes  ?

• A62D 1/02 - Fire-extinguishing compositionsUse of chemical substances in extinguishing fires containing or yielding a gas phase, e.g. foams

Abstract

n (1) wherein Neu5Ac is N-acetylneuraminic acid, and n is an integer in the range from 14 to 26 and/or pharmaceutically acceptable salts thereof, a polysaccharide composition comprising the polysialic acid (1), and the use as a medicament, particularly in the therapeutic and/or prophylactic treatment of degenerative, demyelinating and inflammatory diseases of the central nervous system, and degenerative or inflammatory retinal diseases.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof

Abstract

The present invention relates to a method for the diagnosis of a benign oncocytoma and a method to differentiate a benign oncocytoma from malignant renal cell carcinoma, a kit for use in these methods, as well as antibody relating thereto, a hybridoma cell capable of producing the same as well as the uses relating thereto.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to fire-extinguishing foams or concentrates, which include a carbohydrate containing silane surfactant.

IPC Classes  ?

• A62D 1/02 - Fire-extinguishing compositionsUse of chemical substances in extinguishing fires containing or yielding a gas phase, e.g. foams
• A62D 1/00 - Fire-extinguishing compositionsUse of chemical substances in extinguishing fires

Abstract

The present invention relates in a first aspect to a vector nucleic acid suitable for expressing at least one molecule of interest in a prokaryotic cell, in particular a bacterial cell, or on the surface of a prokaryotic cell or released by the prokaryotic cell. In particular, the present invention relates to a vector nucleic acid comprising a nucleic acid sequence encoding a Fim polypeptide. In addition, the present invention relates to a cell containing said vector as well as isolated recombinant protein containing at least a module being a Fim polypeptide and a module being a molecule of interest. In addition, the present invention relates to methods for the production of the molecule of interest using the vector nucleic acid according to the present invention. Finally, the present invention provides a kit of system containing said vector nucleic acid in particular for the production of recombinant molecule of interest.

IPC Classes  ?

• C07K 14/245 - Escherichia (G)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

Disclosed is a method for identifying a candidate subject for anti- vascular endothelial growth factor (VEGF) therapy. The method involves determining the presence of one or more minor alleles at the single nucleotide polymorphisms (SNPs) rs4576072 and/or rs6828477 in the VEGFR2 gene and administering anti-VEGF therapy to the subject when one or more minor alleles are detected.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention refers to compounds of formula: (formula A), wherein R1 is selected from (formula I), (formula II), (formula (III), (formula IV), (formula V), or (formula B), and wherein R2, R3, R4 and R5 are as defined in the claims and X is OTBS, hydroxy, formyloxy, acetoxy, nitrooxy, nitrooxymethyl, or a halogen; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neoplastic or proliferative disorders, a pharmaceutical composition comprising such a compound and a method preparing this compound.

IPC Classes  ?

• C07C 203/04 - Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
• C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
• C07C 309/76 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
• C07C 247/10 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
• C07F 7/08 - Compounds having one or more C—Si linkages
• A61K 31/621 - Salicylic acidDerivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
• A61K 31/695 - Silicon compounds
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+non-cancer cells. In a further aspect, the present disclosure relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the receptor as well as vectors and cells containing the same. Finally, the present disclosure relates to the use of the chimeric antigen receptor for use in improving persistence and amplification of lymphocyte containing the same and the use of specific peptides for improving persistence and amplification of genetically modified lymphocytes expressing the same.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/14 - BloodArtificial blood
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

The present invention relates to novel fusion genes comprising NRG1 and a further fusion partner, like CD74. The present invention provides for the use of these fusion genes in diagnosis as well as in medical intervention in cancer.

IPC Classes  ?

• C07K 14/74 - Major histocompatibility complex [MHC]
• C07K 14/82 - Translation products from oncogenes

Abstract

The present invention relates to an inhibitor of neurocalcin delta (NCALD) for use in a method for the treatment or prevention of a patient suffering from a disorder associated with a pathological calcium homeostasis. Furthermore, the present invention refers to the use of such inhibitor of NCALD for inducing axon proliferation in vitro and to a method for the differentiation and/or maturation of neuronal stem cells (NSCs) in vitro and to the use of such inhibitor of NCALD to restore impaired endocytosis being a consequence of disturbed Ca2+ homeostasis in synaptic terminals essential for development, maturation and maintenance of synapses and neuromuscular junctions (NMJs).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to a diagnostic in vitro method for determining the activity of thiopurine S-methyltransferase (TPMT) in individuals to be examined, characterised in that the concentration of urothione and/or jukathione in bodily fluids is determined. The invention further relates to a diagnostic in vitro method for determining the TPMT activity in cellular extracts of test subjects of any origin, characterised in that molybdenum cofactor (Moco) and/or degradation stages of Moco are used as substrates for the reaction and the formed amount of jukathione and/or urothione is determined. Finally, the invention relates to a diagnostic in vitro method, wherein urothione and/or jukathione is used as a biomarker for increased susceptibility to one or more certain diseases, which biomarker is identified in bodily fluids and/or cellular extracts.

IPC Classes  ?

• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase

Abstract

The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

IPC Classes  ?

• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07D 471/20 - Spiro-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides